Profile of Cardiovascular Risk Factors and Mortality in Patients with Symptomatic Peripheral Arterial Disease

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2009 Jun 3

PMID 19488590

Citations 7

Authors

Silmeia Garcia Zanati

Guilherme Grisi Mouraria

Luiz Shigero Matsubara

Mariangela Giannini

Beatriz B Matsubara

Affiliations

Soon will be listed here.

Abstract

Introduction: The present study examines cardiovascular risk factor profiles and 24-month mortality in patients with symptomatic peripheral arterial disease.

Design Study: Prospective observational study including 75 consecutive patients with PAD (67 +/- 9.7 years of age; 52 men and 23 women) hospitalized for planned peripheral vascular reconstruction. Doppler echocardiograms were performed before surgery in 54 cases. Univariate analyses were performed using Student's t-test or Fisher's exact test. Survival analysis at 24-month follow-up was performed using the Cox regression model and Kaplan-Meier method including age and chronic use of aspirin as covariates. Survival curves were compared using the log-rank test.

Results: Hypertension and smoking were the most frequent risk factors (52 cases and 51 cases, respectively), followed by diabetes (32 cases). Undertreated dyslipidemia was found in 26 cases. Fasting glycine levels (131 +/- 69.1 mg/dl) were elevated in 29 cases. Myocardial hypertrophy was found in 18 out of 54 patients. Thirty-four patients had been treated with aspirin. Overall mortality over 24 months was 24% and was associated with age (HR: 0.064; CI95: 0.014-0.115; p=0.013) and lack of use of aspirin, as no deaths occurred among those using this drug (p<0.001). No association was found between cardiovascular death (11 cases) and the other risk factors.

Conclusion: There is a high prevalence of uncontrolled (treated or untreated) cardiovascular risk factors in patients undergoing planned peripheral vascular reconstruction, and chronic use of aspirin is associated with reduced all-cause mortality in these patients.

Citing Articles

Clinical and Cardiovascular Profile in Patients With Peripheral Artery Disease.

Bardooli F, Al Agha R, Kumar D Cureus. 2023; 15(5):e39586.

PMID: 37384087 PMC: 10293913. DOI: 10.7759/cureus.39586.

Detecting Peripheral Arterial Disease in Primary Care: A Population Based Study.

Vural T, Tan M, Kartal M, Guldal A Korean J Fam Med. 2019; 41(1):61-67.

PMID: 31079441 PMC: 6987029. DOI: 10.4082/kjfm.18.0066.

Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of north India.

Aiman U, Haseen M, Beg M, Khan R, Siddiqui F, Alam I Indian J Pharm Sci. 2015; 76(6):504-9.

PMID: 25593383 PMC: 4293681.

Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease.

Ma S, Wei C, Hong B, Yu W Clinics (Sao Paulo). 2011; 66(10):1677-80.

PMID: 22012037 PMC: 3180151. DOI: 10.1590/s1807-59322011001000003.

C-Reactive protein predicts acute myocardial infarction during high-risk noncardiac and vascular surgery.

Martins O, Fonseca V, Borges I, Martins V, Portal V, Pellanda L Clinics (Sao Paulo). 2011; 66(5):773-6.

PMID: 21789379 PMC: 3109374. DOI: 10.1590/s1807-59322011000500011.

References

Faxon D, Creager M, Smith Jr S, Pasternak R, Olin J, Bettmann M . Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004; 109(21):2595-604. DOI: 10.1161/01.CIR.0000128517.52533.DB. View

Grundy S, Benjamin I, Burke G, Chait A, Eckel R, Howard B . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100(10):1134-46. DOI: 10.1161/01.cir.100.10.1134. View

Rehring T, Sandhoff B, Stolcpart R, Merenich J, Hollis Jr H . Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg. 2005; 41(5):816-22. DOI: 10.1016/j.jvs.2005.01.047. View

Ouriel K . Peripheral arterial disease. Lancet. 2001; 358(9289):1257-64. DOI: 10.1016/S0140-6736(01)06351-6. View

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of.... J Am Soc Echocardiogr. 2005; 18(12):1440-63. DOI: 10.1016/j.echo.2005.10.005. View

Felicio J, Pacheco J, Ferreira S, Plavnik F, Moises V, Kohlmann Jr O . Hyperglycemia and nocturnal systolic blood pressure are associated with left ventricular hypertrophy and diastolic dysfunction in hypertensive diabetic patients. Cardiovasc Diabetol. 2006; 5:19. PMC: 1579206. DOI: 10.1186/1475-2840-5-19. View

Mukherjee D, Lingam P, Chetcuti S, Grossman P, Moscucci M, Luciano A . Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation. 2002; 106(15):1909-12. DOI: 10.1161/01.cir.0000035649.39669.ce. View

Hertzer N, Beven E, Young J, OHara P, Ruschhaupt 3rd W, Graor R . Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984; 199(2):223-33. PMC: 1353337. DOI: 10.1097/00000658-198402000-00016. View

STRONG J . Atherosclerotic lesions. Natural history, risk factors, and topography. Arch Pathol Lab Med. 1992; 116(12):1268-75. View

10.

Faulkner K, House A, Castleden W . The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983; 1(5):217-9. DOI: 10.5694/j.1326-5377.1983.tb99395.x. View

11.

Smith Jr S, Allen J, Blair S, Bonow R, Brass L, Fonarow G . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006; 47(10):2130-9. DOI: 10.1016/j.jacc.2006.04.026. View

12.

Stiefel P, Miranda M, Rodriguez-Puras M, Garcia-Morillo S, Carneado J, Pamies E . Glucose effectiveness is strongly related to left ventricular mass in subjects with stage I hypertension or high-normal blood pressure. Am J Hypertens. 2004; 17(2):146-53. DOI: 10.1016/j.amjhyper.2003.09.015. View

13.

Wachtell K, Rokkedal J, Bella J, Aalto T, Dahlof B, Smith G . Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol. 2001; 87(1):54-60. DOI: 10.1016/s0002-9149(00)01272-8. View

14.

Hirsch A, Halverson S, Hotvedt P, Lunzer M, Krook S, Rajala S . The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med. 2001; 6(2):87-96. DOI: 10.1177/1358836X0100600204. View

15.

Belch J, Topol E, Agnelli G, Bertrand M, Califf R, Clement D . Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163(8):884-92. DOI: 10.1001/archinte.163.8.884. View

16.

Murabito J, DAgostino R, Silbershatz H, Wilson W . Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997; 96(1):44-9. DOI: 10.1161/01.cir.96.1.44. View

17.

Kitzman D, Gardin J, Gottdiener J, Arnold A, Boineau R, Aurigemma G . Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001; 87(4):413-9. DOI: 10.1016/s0002-9149(00)01393-x. View